Author(s): Wallis RS
Abstract Share this page
Abstract In the decade since tumor necrosis factor α (TNF-α) antagonists were first approved for clinical use, they have proven invaluable for the treatment of specific types of chronic inflammation. Currently licensed TNF blockers fall into two classes, monoclonal antibody (or antibody fragments) and soluble receptor. Although they are equally effective in rheumatoid arthritis and psoriasis, important differences have emerged with regard to efficacy in granulomatous inflammation and risks of granulomatous infections, particularly tuberculosis. This article focuses on recent studies that inform prevention and management of infections in this susceptible patient population. Copyright Â© 2011 Elsevier Inc. All rights reserved.
This article was published in Infect Dis Clin North Am
and referenced in Journal of Transplantation Technologies & Research